After finishing at $22.68 in the prior trading day, Myriad Genetics Inc. (NASDAQ: MYGN) closed at $22.94, up 1.15%. In other words, the price has increased by $+0.26 from its previous closing price. On the day, 753760 shares were traded. MYGN stock price reached its highest trading level at $23.23 during the session, while it also had its lowest trading level at $22.07.
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
Our goal is to gain a better understanding of MYGN by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.70 and its Current Ratio is at 1.80. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 27 when Lambert Nicole sold 6,433 shares for $23.48 per share. The transaction valued at 151,047 led to the insider holds 240,506 shares of the business.
Riggsbee Richard Bryan sold 15,000 shares of MYGN for $338,253 on Mar 02. The Chief Financial Officer now owns 337,885 shares after completing the transaction at $22.55 per share. On Mar 02, another insider, Lambert Nicole, who serves as the Chief Operating Officer of the company, sold 13,184 shares for $22.74 each. As a result, the insider received 299,823 and left with 215,220 shares of the company.
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MYGN now has a Market Capitalization of 1.72B and an Enterprise Value of 1.80B. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.61 while its Price-to-Book (P/B) ratio in mrq is 2.23. Its current Enterprise Value per Revenue stands at 2.60 whereas that against EBITDA is -17.19.
Stock Price History:
Over the past 52 weeks, MYGN has reached a high of $28.18, while it has fallen to a 52-week low of $13.92. The 50-Day Moving Average of the stock is 21.66, while the 200-Day Moving Average is calculated to be 20.38.
The stock has traded on average 614.21K shares per day over the past 3-months and 479.13k shares per day over the last 10 days, according to various share statistics. A total of 81.30M shares are outstanding, with a floating share count of 79.43M. Insiders hold about 3.00% of the company’s shares, while institutions hold 102.49% stake in the company. Shares short for MYGN as of May 14, 2023 were 3.77M with a Short Ratio of 3.68M, compared to 3.74M on Apr 13, 2023. Therefore, it implies a Short% of Shares Outstanding of 4.63% and a Short% of Float of 6.65%.
Its stock is currently analyzed by 8 different market analysts. On average, analysts expect EPS of -$0.08 for the current quarter, with a high estimate of $0 and a low estimate of -$0.12, while EPS last year was $0.04. The consensus estimate for the next quarter is -$0.07, with high estimates of -$0.02 and low estimates of -$0.14.
Analysts are recommending an EPS of between -$0.25 and -$0.37 for the fiscal current year, implying an average EPS of -$0.32. EPS for the following year is $0.07, with 10 analysts recommending between $0.28 and -$0.13.
9 analysts predict $187.04M in revenue for the current quarter. It ranges from a high estimate of $189.94M to a low estimate of $185M. As of the current estimate, Myriad Genetics Inc.’s year-ago sales were $179.3M, an estimated increase of 4.30% from the year-ago figure. For the next quarter, 9 analysts are estimating revenue of $180.39M, an increase of 6.00% over than the figure of $4.30% in the same quarter last year. There is a high estimate of $188M for the next quarter, whereas the lowest estimate is $174.6M.
A total of 10 analysts have provided revenue estimates for MYGN’s current fiscal year. The highest revenue estimate was $746.98M, while the lowest revenue estimate was $738M, resulting in an average revenue estimate of $742.08M. In the same quarter a year ago, actual revenue was $678.4M, up 9.40% from the average estimate. Based on 10 analysts’ estimates, the company’s revenue will be $800.11M in the next fiscal year. The high estimate is $809.3M and the low estimate is $784.35M. The average revenue growth estimate for next year is up 7.80% from the average revenue estimate for this year.